Total Payments
$4,372
2022 Payments
$28.08
Companies
36
Transactions
191
Medicare Patients
1,134
Medicare Billing
$102,442
Payment Breakdown by Category
Food & Beverage$4,372 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,372 | 191 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $453.91 | 8 | $0 (2021) |
| Bayer HealthCare Pharmaceuticals Inc. | $395.13 | 15 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $368.27 | 19 | $0 (2020) |
| GlaxoSmithKline, LLC. | $304.10 | 18 | $0 (2018) |
| Exelixis Inc. | $250.00 | 2 | $0 (2021) |
| Daiichi Sankyo Inc. | $217.16 | 7 | $0 (2021) |
| Taiho Oncology, Inc. | $212.85 | 13 | $0 (2022) |
| AbbVie, Inc. | $182.59 | 6 | $0 (2018) |
| Eisai Inc. | $178.96 | 4 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $163.07 | 5 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $28.08 | 2 | Taiho Oncology, Inc. ($14.29) |
| 2021 | $1,002 | 13 | AstraZeneca Pharmaceuticals LP ($374.96) |
| 2020 | $526.84 | 14 | Bayer HealthCare Pharmaceuticals Inc. ($186.58) |
| 2019 | $1,137 | 60 | Merck Sharp & Dohme Corporation ($223.12) |
| 2018 | $791.12 | 50 | AbbVie, Inc. ($166.07) |
| 2017 | $886.94 | 52 | GlaxoSmithKline, LLC. ($212.61) |
All Payment Transactions
191 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/13/2022 | Taiho Oncology, Inc. | LONSURF (Drug) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: Oncology | ||||||
| 10/13/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.79 | General |
| Category: Neuroscience | ||||||
| 08/09/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 07/26/2021 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $10.35 | General |
| Category: ONCOLOGY | ||||||
| 06/28/2021 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 06/25/2021 | Taiho Oncology, Inc. | Lonsurf (Drug) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: Oncology | ||||||
| 04/27/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 04/12/2021 | Ipsen Biopharmaceuticals, Inc | ONIVYDE (Drug) | Food and Beverage | In-kind items and services | $124.98 | General |
| Category: Oncology | ||||||
| 03/31/2021 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $5.19 | General |
| Category: ONCOLOGY | ||||||
| 03/29/2021 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $5.26 | General |
| Category: ONCOLOGY | ||||||
| 03/22/2021 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONCOLOGY | ||||||
| 03/16/2021 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: Oncology | ||||||
| 03/15/2021 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $124.96 | General |
| Category: Oncology | ||||||
| 03/09/2021 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 02/26/2021 | Bayer HealthCare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $74.00 | General |
| Category: Oncology | ||||||
| 12/18/2020 | Bayer HealthCare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $74.00 | General |
| Category: Oncology | ||||||
| 12/14/2020 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $123.04 | General |
| Category: Oncology | ||||||
| 09/23/2020 | Taiho Oncology, Inc. | Lonsurf (Drug) | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: Oncology | ||||||
| 08/07/2020 | Taiho Oncology, Inc. | Lonsurf (Drug) | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: Oncology | ||||||
| 07/15/2020 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Oncology | ||||||
| 07/10/2020 | Taiho Oncology, Inc. | Lonsurf (Drug) | Food and Beverage | In-kind items and services | $11.74 | General |
| Category: Oncology | ||||||
| 03/09/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $11.41 | General |
| Category: ONCOLOGY | ||||||
| 02/14/2020 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug), Nexavar | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: Oncology | ||||||
| 01/29/2020 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug) | Food and Beverage | In-kind items and services | $11.54 | General |
| Category: Oncology | ||||||
| 01/24/2020 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 195 | 233 | $55,660 | $15,774 |
| 2022 | 4 | 204 | 257 | $52,716 | $17,916 |
| 2021 | 7 | 338 | 438 | $88,771 | $29,831 |
| 2020 | 7 | 397 | 537 | $127,612 | $38,920 |
Total Patients
1,134
Total Services
1,465
Medicare Billing
$102,442
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 76 | 77 | $26,577 | $7,496 | 28.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 41 | 70 | $12,807 | $4,149 | 32.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 47 | 54 | $4,878 | $2,072 | 42.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 18 | 19 | $7,754 | $1,406 | 18.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 13 | 13 | $3,644 | $651.43 | 17.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 93 | 102 | $28,828 | $10,353 | 35.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 64 | 101 | $15,169 | $5,296 | 34.9% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 32 | 39 | $3,044 | $1,168 | 38.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 15 | 15 | $5,675 | $1,099 | 19.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 110 | 121 | $32,670 | $12,753 | 39.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 107 | 180 | $25,380 | $9,914 | 39.1% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 53 | 65 | $4,940 | $1,953 | 39.5% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 20 | 20 | $7,100 | $1,725 | 24.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 18 | $6,670 | $1,225 | 18.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 11 | 11 | $7,040 | $1,180 | 16.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 22 | 23 | $4,971 | $1,080 | 21.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 119 | 128 | $35,378 | $14,088 | 39.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 132 | 240 | $34,280 | $13,792 | 40.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 36 | 47 | $17,980 | $2,634 | 14.7% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 26 | 26 | $19,121 | $2,479 | 13.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 14 | 14 | $5,558 | $2,254 | 40.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 54 | 66 | $5,055 | $2,069 | 40.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 16 | 16 | $10,240 | $1,604 | 15.7% |
About Dr. Chad Sisk, D.O
Dr. Chad Sisk, D.O is a Gastroenterology healthcare provider based in Guntersville, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922197045.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Chad Sisk, D.O has received a total of $4,372 in payments from pharmaceutical and medical device companies, with $28.08 received in 2022. These payments were reported across 191 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($4,372).
As a Medicare-enrolled provider, Sisk has provided services to 1,134 Medicare beneficiaries, totaling 1,465 services with total Medicare billing of $102,442. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology
- Location Guntersville, AL
- Active Since 10/12/2006
- Last Updated 01/21/2025
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1922197045
Products in Payments
- CABOMETYX (Drug) $250.00
- LYNPARZA (Drug) $250.00
- Lonsurf (Drug) $198.56
- Creon (Drug) $182.59
- Lenvima (Drug) $178.96
- Stivarga (Drug) $175.21
- Enhertu (Drug) $145.80
- ONIVYDE (Drug) $124.98
- TAGRISSO (Drug) $124.96
- NUCALA (Biological) $117.89
- DIFICID (Drug) $114.07
- TRELEGY ELLIPTA (Drug) $100.74
- XIFAXAN (Drug) $96.08
- Amitiza (Drug) $87.53
- ACTHAR (Biological) $80.64
- IMFINZI (Drug) $78.95
- Nubeqa (Drug) $74.00
- Xofigo (Drug) $74.00
- KEYTRUDA (Biological) $73.14
- SANDOSTATIN (Drug) $61.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.